跳到正文
原文
Medical Xpress·· 1 天前精选AI 评分70

mRNA疫苗增强细胞免疫疗法治疗胶质母细胞瘤获初步突破

An mRNA booster for cellular immunotherapy shows potential against aggressive brain tumors

AI 导读

德国癌症研究中心(DKFZ)与曼海姆大学医学中心(UMM)团队研究发现,针对胶质母细胞瘤的TCR-T细胞疗法联合mRNA疫苗可显著提升治疗效果。mRNA疫苗使树突状细胞展示肿瘤特征蛋白,从而放大T细胞扩增及脑内浸润能力;在小鼠模型中,部分受试动物血液内治疗性T细胞占比高达80%,且部分病例肿瘤完全消退。

推荐理由

德国DKFZ与UMM团队在Cancer Research发表研究,mRNA疫苗可显著增强TCR-T细胞疗法对抗胶质母细胞瘤的活性与脑浸润能力,为后续临床试验提供基础。

正文
brain tumor
Credit: cottonbro studio from Pexels

A team led by researchers at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) has developed a new approach to more effectively direct immune cells against glioblastomas. In experimental models, they were able to show that a targeted mRNA vaccine significantly increases the potency of therapeutic immune cells. The paper is published in the journal Cancer Research.

The vaccine not only ensures that the cancer-fighting T cells proliferate rapidly, but it also facilitates their entry into the brain, where they can attack the tumors. The results open up new avenues for the development of more effective immunotherapies against this aggressive form of cancer.

Glioblastomas are considered the most aggressive form of brain cancer. Despite surgery, radiation and chemotherapy, the tumors often recur. High hopes are therefore pinned on immunotherapies that specifically activate the body's own immune cells to attack cancer cells. However, such treatments have so far reached their limits, particularly when it comes to brain tumors: Too few of the therapeutic immune cells reach the tumor—and once there, they often lose their activity.

A research team led by Lukas Bunse (head of the Neuro-Oncology Section at UMM and a scientist at the DKFZ) and Michael Platten (director of the University Clinic for Neurology at UMM and head of department at the DKFZ) has now investigated how these obstacles can be overcome. Their idea: An mRNA vaccine targeting the tumor's protein markers is intended to give the cancer-targeting therapeutic immune cells an extra boost.

A booster for tailored immune cells

The study focuses on a therapy using T cells that have been genetically engineered in the laboratory to express a specific recognition molecule. This so-called T-cell receptor enables them to recognize a specific feature of the tumor cells—much like an antenna—and to target the cancer. Experts refer to these as "T-cell receptor-transgenic T cells."

However, simply transferring the therapeutic immune cells to the patient is often not enough. Researchers must also ensure that the transgenic T cells multiply in the body, remain active over the long term and reach the tumor in sufficient numbers.

This is where the mRNA vaccination comes in. The mRNA provides another group of immune cells—dendritic cells—with instructions for producing a characteristic feature of the tumor.

The dendritic cells then present a kind of "tumor profile" on their surface, which alerts the therapeutic T cells to the cancer's characteristics. In this way, the vaccination acts as an amplifier for a cellular immunotherapy that is already specifically targeted against the tumor.

Immune cells proliferate massively and penetrate the brain more effectively

In mice with experimental glioblastomas, the combination of therapeutic TCR-T cells and mRNA vaccination showed remarkable efficacy: The transferred immune cells proliferated so extensively that at times they accounted for up to 80% of all killer T cells in the mice's blood.

However, it was not just their number that was decisive; the vaccination also altered the properties of the therapeutic T cells. Thanks to this additional activation, more T cells were able to migrate into the brain tumors. Once there, they remained particularly effective at attacking the tumor and showed fewer signs of functional exhaustion.

This was reflected in the treatment's success: While tumors continued to grow in untreated animals or those receiving low-dose monotherapy, the combination therapy was able to significantly slow tumor growth—in some cases, even in all animals in a given experimental series. The animals' survival time also increased significantly.

Combination therapy also effective against human glioblastomas in a mouse model

To determine whether this principle could be applied to the treatment of patients with glioblastomas, the research team conducted experiments using human immune cells. These T cells were equipped with a receptor that specifically recognizes the PTPRZ1 protein. PTPRZ1 is present on human glioblastoma stem cells, which drive tumor growth.

The researchers tested the combination of PTPRZ1-specific therapeutic T cells plus mRNA enhancement both in cell experiments and in mice bearing human glioblastomas. The additional mRNA stimulation enhanced the ability of the therapeutic T cells to kill the human brain tumors. In some cases, the tumors in the animals regressed completely. However, the combination of the two approaches did not result in more severe side effects.

"The results provide us with important insights into how cell-based immunotherapies against brain tumors can be improved. In the long term, the combination could, for example, make it possible to use a lower initial dose of therapeutic T cells. This could potentially simplify the labor-intensive process of proliferating T cells in the laboratory," says Andreas Dobbelstein, first author of the study.

"We are already preparing an initial clinical trial for the treatment of glioblastomas with PTPRZ1-targeted TCR-T cells. The combination with mRNA-based stimulation that we have now investigated could serve as a foundation for further clinical developments," adds Bunse.

Platten emphasizes that the evaluation of the combination therapy is still in the preclinical research phase. "Whether the mRNA booster, in combination with cellular immunotherapy, is also safe and effective in patients must first be investigated in clinical trials."

Publication details

Andreas D. Dobbelstein et al., RNA Vaccination Drives Expansion and Brain-Licensing of T Cells to Enhance the Efficacy of Adoptive Cell Therapy in Glioblastoma, Cancer Research (2026). DOI: 10.1158/0008-5472.can-26-0760

Journal information: Cancer Research

Key medical concepts

Glioblastoma

Clinical categories

OncologyNeurology

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: An mRNA booster for cellular immunotherapy shows potential against aggressive brain tumors (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-mrna-booster-cellular-immunotherapy-potential.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com